Registry for drug response profiling in pediatric blood cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on drug response profiling (DRP) for pediatric patients with hematological malignancies. It involves isolating primary cancer cells from patients and screening them ex vivo using automated fluorescence microscopy to assess drug sensitivity. The study aims to integrate drug sensitivity data with genetic information to provide personalized treatment options for patients with refractory disease. By evaluating the effectiveness of various chemotherapeutic agents, the study seeks to determine the feasibility of real-time drug response profiling in clinical settings.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Pediatric and adult patients below the age of 40 years
* Diagnosis of hematological malignancy (primary, relapsed or refractory) including leukemia, myeloma or lymphoma
* Tumor material collected as part of routine diagnostics and willingness to donate tumor material for translational research
* Patient and/or guardian has signed the informed consent of the DRP registry or of a clinical trial which includes DRP as add-on research.

Exclusion Criteria:

* Missing informed consent for the registry or of a clinical trial which includes DRP as add-on research

Where it's running

• University Children's Hospital Zurich
  Zurich, Canton of Zurich, Switzerland Recruiting

Study contacts

• Study coordinator: Jean-Pierre Bourquin, MD, PhD
• Email: Jean-Pierre.Bourquin@kispi.uzh.ch
• Phone: 0041 44 2667304

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Lower Dose Cyclophosphamide After Haploidentical Stem Cell Transplant

  This trial tests whether giving half the usual amount of cyclophosphamide after haploidentical stem cell transplantation can still prevent GVHD in adults with blood cancers.

  Recruiting Phase 2 Tata Memorial Centre · Navi Mumbai, Maharashtra and 1 other locations · NCT07719946

• Chlorophyllin to reduce mouth sores before allogeneic stem cell transplant

  This phase II study tests whether taking chlorophyllin by mouth can lower the chances and severity of mouth ulcers in patients aged 12–65 undergoing radiation-based conditioning before a first allogeneic stem cell transplant.

  Recruiting Phase 2 Tata Memorial Centre · Navi Mumbai, Maharashtra · NCT07709195

• First-in-human test of DS3790a for hematological malignancies

  This first-in-human trial will test DS3790a alone and with other drugs to see if it's safe, how it behaves in the body, and whether it helps adults with hematological malignancies.

  Recruiting at 8 sites Phase 1/2 Daiichi Sankyo · New York, New York and 7 other locations · NCT07220616

• 18F‑Pentixafor PET imaging for blood cancers

  This will test whether 18F‑Pentixafor PET scans help diagnose, stage, and check treatment response in adults with suspected or confirmed hematologic malignancies.

  Recruiting First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang · NCT07122674

• Improving GVHD prevention after donor stem cell transplant

  This study will test whether a lower dose versus the standard dose of post-transplant cyclophosphamide, given with sirolimus and MMF, improves quality of life for people aged 60 and older having a reduced-intensity allogeneic stem cell transplant.

  Recruiting Phase 2 University of Nebraska · Omaha, Nebraska · NCT06799195

• Long-term follow-up for patients treated with Galapagos CAR T-cell therapies

  This study is checking how well Galapagos CAR T-cell therapies work and their safety for patients over 15 years after treatment.

  Recruiting at 11 sites Phase 3 Lakefront Biotherapeutics NV · Boston, Massachusetts and 10 other locations · NCT06652633

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.